Adjuvant chemotherapy fails to provide a short-term survival benefit to patients with advanced nasopharyngeal carcinoma {#s1}
=======================================================================================================================

Since 1998, concurrent chemoradiotherapy plus adjuvant chemotherapy has been regarded as the standard treatment for advanced nasopharyngeal carcinoma (NPC). However, in recent years, several randomized phase III trials testing this treatment strategy showed controversial results, raising questions about whether adjuvant chemotherapy provides an additional survival benefit over concurrent chemoradiotherapy. Professor Jun Ma and colleagues organized an open-label phase III multicenter randomized controlled trial at seven institutions in China. Their results, which were published in *Lancet Oncology*, showed that adjuvant chemotherapy did not improve the 2-year failure-free survival of patients with locoregionally advanced NPC after concurrent chemoradiotherapy. Thus the authors recommend that adjuvant chemotherapy should not be considered as a standard treatment for advanced NPC, hoping to avoid the overtreatment of these patients and to decrease the side effects as well as the additional cost of chemotherapy.

In this trial, 508 patients were enrolled and randomized to the concurrent chemoradiotherapy plus adjuvant chemotherapy group (*n* = 251) or the concurrent chemoradiotherapy alone group(*n* = 257). After a median follow-up of 37.8 months, no significant difference in the estimated 2-year failure-free survival was found between the two groups (86% vs. 84%, hazard ratio = 0.74, *P* = 0.13). There was also no difference in incidence and grade of toxicities between the two groups during radiotherapy (63% vs. 61% for grade 3 to 4 toxic effects, *P* = 0.78). However, 87 (42%) of 205 patients in the concurrent chemoradiotherapy plus adjuvant chemotherapy group further experienced grade 3 to 4 toxic effects during adjuvant chemotherapy. These findings suggest that adjuvant chemotherapy with cisplatin and 5-fluorouracil did not provide a survival benefit to concurrent chemoradiotherapy in patients with locoregionally advanced NPC.

The authors proposed three possible reasons for the lack of benefit from adjuvant chemotherapy. First, the administered adjuvant regimen of cisplatin and 5-fluorouracil might not be an optimal combination for treating micrometastases in NPC. Second, the survival gain from the concurrent chemoradiotherapy may have lessened the additional gain from adjuvant chemotherapy. Third, only patients with a high regional tumor burden were enrolled in this study; but cisplatin and 5-fluorouracil may only benefit patients having a low regional tumor burden. The authors will continue patient follow-up and will report 5-year findings to more fully document survival and late toxic effects.
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